why is everyone taking glp 1 GLP-1 receptor agonists Should everyone be on GLP-1s?
Description
Novo Nordisk, EVOKE and EVOKE+ phase 3 trial topline results, Alzheimers Association statement, 2025
Metseras pipeline includes MET-097i, a GLP-1 receptor agonist designed for once-monthly dosing, and MET-233i, an amylin analog being developed for monthly administration
They're moderating with intention
The experimental (hops) group also reported a reduction in cravings for savory and sweet foods compared to placebo [1]
Plus: Canadas generic pricing framework explained.
